
PolarityTE Inc (AKA: RegenETP Inc~PolarityTE MD Inc) Profile last edited on: 12/2/2023
CAGE: 8DM08
UEI: LMTQKMVNFVN7
Business Identifier: Translational regenerative medicine company Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 02
County: Salt Lake
Congr. District: 02
County: Salt Lake
Public Profile
PolarityTE is a publicly traded (NASDAQ:PTE) commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovery, design and development of a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. The PolarityTE platform technology begins with a small piece of the patient's own, or autologous, healthy tissue, rather than artificially manipulated individual cells. From this small piece of healthy autologous tissue, the company creates an easily deployable, dynamic and self-propagating product designed to enhance and stimulate the patient's own cells to regenerate the target tissues. Rather than manufacturing with synthetic and foreign materials within artificially engineered environments, PolarityTE manufactures with the patient's own tissue and uses the patient's own body to support the regenerative process to create the same tissue from which it was derived. PolarityTE's innovative method is intended to promote and accelerate growth of the patient's tissues to undergo a form of effective regenerative healing.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
50-74Revenue Range
5M-7.5MVC funded?
YesPublic/Private
Publicly TradedStock Info
NASDAQ : PTEIP Holdings
15-19Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2020 | 1 | NIH | $244,894 | |
Project Title: Fluid Management System for Point of Care Device for Novel Regenerative Treatment for Chronic Wounds |
Key People / Management
David B Seaburg -- Chief Executive Officer
Kolby Day -- Senior Vice President Operations, Corporate General Manager
Rich Haerle -- VP of Investor Relations & Strategy
Richard Hague -- Chief Operating Officer
Cameron J Hoyler -- Gen. Counsel, Sec. and Exec. VP of Corp. Devel. & Strategy
Jacob Alexander Patterson -- Interim Chief Financial Officer
Jacqueline Reed -- TitleDirector of Grants and Contracts
Nikolai Anton Sopko -- Chief Scientific Officer and VP of R&D
Kolby Day -- Senior Vice President Operations, Corporate General Manager
Rich Haerle -- VP of Investor Relations & Strategy
Richard Hague -- Chief Operating Officer
Cameron J Hoyler -- Gen. Counsel, Sec. and Exec. VP of Corp. Devel. & Strategy
Jacob Alexander Patterson -- Interim Chief Financial Officer
Jacqueline Reed -- TitleDirector of Grants and Contracts
Nikolai Anton Sopko -- Chief Scientific Officer and VP of R&D